C-N40UJuvena Therapeutics
secreted proteins, AI-enabled biologics, protein engineering
repairingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-N40U
C-N40UC-N40Usecreted proteins, AI-enabled biologics, protein engineering
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This is a double-blind, placebo-controlled, randomized study of 96 days total duration to assess the effect of JUV-161 on muscle disuse atrophy. This will be a multicenter study in New Zealand and will include up to 40 healthy volunteers aged between 40 to 65 years of age. Following the screening period, subjects will be randomized to receive either weekly subcutaneous (SC) injections of one of two doses of JUV-161 or matching placebo for a period of approximately 6 weeks.
The present First-In-Human (FIH) study (JUV-161-101) aims to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple subcutaneous (SC) doses of JUV-161 in healthy volunteers. The study design is well-established for FIH studies and appropriate to assess the preliminary safety and tolerability of new drug candidates. Data from this study will support conduct studies in patients with DM1 as well as supporting studies in other degenerative myopathies and other disorders for which preclinical efficacy data have been obtained.JUV-161 has not been previously been administered to human subjects.
Metabolic Collaboration and Licensing Agreements Benchmark Report 2026: Access Structured Analysis of 639 - Financial Terms, Upfronts, Stage, Asset Type, Milestones, and Royalties Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management B … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets closed UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets closed FTSE 100 10,508.02 -21.87 -0.21% GBP/USD 1.3198 +0.0001 +0.00% GBP/EUR 1.1589 -0.0008 -0.07% FTSE 250 23,147.19 -14.22 -0.06% AIM 770.35 -1.57 -0.20% GOLD FUTURES 4,096.30 +48.70 +1.20% ADVERTIS … im Eracal Therapeutics Eton Pharmaceuticals European Union Regional Development Fund European Wellness Biomedical Group EVA Pharma EverlyWell Eversana EVerZom Evgen Pharma Evidation Health Evo Foods EVOQ Therapeutics Evotec Evozyne Ewopharma ExCEEd Orphan Fermbox Bio First Wave Bio FitBit Flagship Biosciences G3 Therapeutics G42 Healthcare Gain Therapeutics Galapagos Galectin Therapeutics Galmed Pharmaceuticals Gan & Lee Gannex Pharma Gastrologix GATC Health GC Pharma GE Heal
%PDF-1.6 %���� 393 0 obj > endobj 405 0 obj >/Filter/FlateDecode/ID[ ]/Index[393 22]/Info 392 0 R/Length 73/Prev 314822/Root 394 0 R/Size 415/Type/XRef/W[1 2 1]>>stream h�bbd``b` 3��!�`�L�@�k!��$�����4�P��a L�� � ��� �? �) endstream endobj startxref 0 %%EOF 414 0 obj >stream h�b```�J�d!b`B�F$A��� ��������� c �*&���c8ř�� Pq�X��ǐŠ��[���!i��3H�۱�n�n�����!d�� GK�zw-��.�5]TO+!��=� ���������������I4p@D"@"!0����Dh40��]������ >�X~p0�;OX���I��n`�� ,+ i`P �µ[2�����X��n[� endstream endobj 394 0 obj >/Metadata 55 0 R/PageLayout/OneColumn/Pages 387 0 R/S … 8f175-900f-4ac6-a6a4-7f497306ff27 uuid:ba8ee515-ea52-4c37-ae81-efc250c701cd 101 application/pdf Stella McCormick Adobe PDF Library 24.2.121 15cedf245304fbf373cc0e981654b276c5c2f7927274ec7b4770921eaa0b96c2 endstream endobj 56 0 obj >stream hޔ�1�0 E��$��4��.�,Uņ*Q!@nO�_A]���ck�ɓ�DQJdbM�ٓp]�Ir��q���� ���|��3勺�e) y۽n���8����)��`C)��M(w�},�����.�\d �� t�@'�� �e��,�)|��a H���#� � n endstream endobj 57 0 obj >stream h�l�AK�0�ῒ۶��4m�, �E��P�s2�bݶ�1E��ME � >/Fil
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Eli Lilly partners with Juvena for muscle health drugs | Awanish Pandey, PhD posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, yo … w or add a comment, sign in Césaré Cejas 8mo Report this post This year's Nobel Prize for Physiology or Medicine is an excellent moment for the advanced therapeutics industry. Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi discovered how the "immune system is kept in check," identifying regulatory T-cells (or T-regs), which prevents immune cells from attacking our own body. T-regs are particularly important in autologous cell therapies by suppressing/preventing excessive … n with the MFX Development Engine, our newly improved automated platform, as we apply statistically powered DoE (design-of-experiments) to allow users to vary different parameters (e.g. gas feed, media exchange, agitation) whilst acquiring non-invasive real-time data (e.g. metabolites, pH, dO) to accelerate their process development, a typically labour- and resource-intensive step in therapy manufacturing. This was work done with Michael Delahaye 's group, together with Gabri
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Juvena Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases - Juvena Therapeutics News Back to Careers Juvena Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases Navigation Home Platform Disease Indications Pipeline Team Join Us News Contact Us Home Platform Disease Indications Pipeline Team Join Us News Contact Us Contact 640 Galveston Drive Redwood City, CA 94063 Get Directions » 650.223.5879 [email protected] Stay in touch Subscribe to our newsletter Email Sub
Refresh your skin and stay cool with Juvena’s Orange & Tea Tree Body Wash! This deep cleansing formula combines a shot of citrusy orange with the soothing power of tea tree oil to help you beat the heat. Get ready for a total freshness upgrade and a revitalizing shower experience. 📍 Visit- D57/60, A-1K, Siddhgiri Bagh, Road, Sigra, Varanasi, Uttar Pradesh 221002 📞 Book your appointment today!- +91 9278358655 ➡️ Buy Products from our online store🛒.(Link In The Bio) Get FREE Consultation...✨ Reach us at 📞-- +91 9278358655 Or Whatsapp us on and we will guide you through the entire recomme
Eli Lilly partners with Juvena for muscle health drugs | Pennsylvania NY NJ Biotech Networks posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to joi
Steven P. James - Ventus Therapeutics --> Ventus Therapeutics Contact ENG About Overview Leadership Board of Directors Founders Advisors Investors Pipeline Pipeline VENT-03 VENT-02 VENT-04 Platform Patients News & Events Latest News Events Media Coverage Careers Overview Open Positions Viewpoints News Making progress and achieving milestones to create innovative medicines About Overview Leadership Board of Directors Founders Advisors Investors Pipeline Pipeline VENT-03 VENT-02 VENT-04 Platform Patients News & Events Latest News Events Media Coverage Careers Overview Open Positions Vi
%PDF-1.4 % ���� 3 0 obj > /PageLabels > ] >> /Outlines 2 0 R /Pages 1 0 R >> endobj 4 0 obj > endobj 5 0 obj > >> endobj 6 0 obj > stream x���{�dGr'VBC�|g��H�YxףrfX��C��Ëf�%������!C��$��%/��1�Ml��sD�+�T֭�S�pz�F��~��q����{q�>H �>�{�7b/��.Xa�'���#���i��QQ�&�F��f� ���7�n��כ�����ǿ7��R������-������� ��� �����ɕ8+ � �c�r��&��(mH`-˰�${��/h�y�O7���o��q�w0� �S��7Nyc%|�R{eM�y�t�>�xpL�4Q��A)T1k����V|�q٦����� ���]�!5j��sp⠈�ʌ�� �bt����㣌2����U�:lj��R��j*ʠmvӺ=,���x�8NZhZ{:� �IS�o��nn�s{���G�`�/_B�/����'����U�������� �i�>�o�L�w����9��n>�rI�*�q�Wԩ���� ����P��ҫ�^�c
Juvena Therapeutics Stock Price, Funding, Valuation, Revenue & Financial Statements Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & Par … 4 11/8/2022 Series A $XXM Subscribe to see more $XXM 0 FY undefined 10 2/2/2022 Grant $XXM Subscribe to see more $XXM 0 FY undefined 10 1/1/2021 Incubator/Accelerator Subscribe to see more $XXM 0 FY undefined 10 2/26/2018 Seed VC $XXM Subscribe to see more $XXM 0 FY undefined 10 Date 7/24/2025 11/8/2022 2/2/2022 1/1/2021 2/26/2018 Round Series B Series A Grant Incubator/Accelerator Seed VC Amount $33.5M $XXM $XXM $XXM Investors Bison Ventures , Alumni Ventures , Eli Lilly and
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Juvena Gets a New ‘Master’ Plan Skip to main content X WWD Footwear News Sourcing Journal WWD Weekend Beauty Inc Fairchild Live Beauty Inc site categories Fragrance Color Cosmetics Hair Beauty Features Skin Care Wellness Body Care WWD Click to expand the Mega Menu Got a Tip? Beauty Inc Click to Expand Search Input Plus Icon Click to Close Search Input Newsletters Account Welcome Manage Account Log Out Log In Sign Up Beauty Skin Care Juvena Gets a New ‘Master’ Plan Swiss skin care brand Juvena is undergoing a total makeover. By Susan Stone Plus Icon Susan Stone Recent Ar … 39; Relationships. Here's What That Means Judge Gives Trump Administration Deadline to Explain Tarp Covering Kennedy Center You May Also Like Knicks Star Jordan Clarkson Walks the Willy Chavarria Spring 2027 Runway in Shorts, Socks and On-trend Loafers 3 hrs ago Fashion Loves Food 2025 9 months ago The Countdown to the USMCA Review is On. Here’s What’s At Stake. 1 hr ago Cash Considerations Ruled the NBA Draft. Here’s How They Work 11 hrs ago Vatican Museums Launch Major … cted by reCAPTCHA Enterprise and the Google Privacy Policy and Terms of Service apply. Have a Tip? Send us a tip using our anonymous form. Send Us a Tip Sign Up WWD and Women's Wear Daily are part of Penske Media Corporation. © 2026 Fairchild Publishing, LLC. All Rights Reserved. Powered by WordPress.com VIP Our Sites Art in America Artforum ARTnews Billboard BlogHer Deadline Flow Space Footwear News Gold Derby IndieWire Robb Report Rolling Stone SheKnows Soaps Sour … cted by reCAPTCHA Enterprise and the Google Privacy Policy and Terms of Service apply. optional screen reader About Us Advertising Help Accessibility Icon Link Plus Icon WWD and Women's Wear Daily are part of Penske Media Corporation. © 2026 Fairchild Publishing, LLC. All Rights Reserved. © 2021 Penske Media Corporation ad
ENDO 2026 Skip to main content Toggle navigation Search Home Facebook Post Print Adipose Tissue_Appetite_and Obesity MON-706 - A Secreted Protein Therapeutic, JUV-161, Improves Muscle Structure and Function in Age-Related Sarcopenia Monday, June 15, 2026 9:00 AM - 2:00 PM CT Location: ENDOExpo; Poster Floor Co-Author(s) AK Ashil Korrane, n/a Juvena Therapeutics Redwood city, California, United States HK Hee Ju Kim, n/a Juvena Therapeutics Redwood city, California, United States Submitting author(s) RD Ritwik Datta, PhD Scientist-II Juvena therapeutics San Francisco, United States Abstract Post
JUV-161 - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 09 Feb 2026 JUV-161 Last update 09 Feb 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Biosimilar Regulation Overview Basic Info Drug Type Fusion protein Synonyms JUV 161, JUV161 Target IGF-2R Action modulators Mechanism IGF-2R modulators(Insulin-like growth factor II receptor modulators) Therapeutic Areas Nervous System Diseases Congenital Disorders Skin and Musculoskeletal Diseases + [2] Active Indication Myo … onfidentiality agreement in April 2024. In February 2025, Party A said it would submit an acquisition proposal, only to later say it was reconsidering the deal due to “recent trading dynamics” and then pull back in April. — Ayisha Sharma 💵 Oricell puts together $70M fundraise: The China-based biotech described the round as a “Series C1” financing. Oricell is attempting to develop CAR-T therapies that can be used in solid tumors, a difficult area that has seen no approvals so … erence in Boston this week, Fierce spoke with a biotech executive who had their grant pulled, as well as an industry thought leader who backed up the claims about a change in the HHS\' funding approach.“I\'m sure that NIA [National Institute of Aging] is not going to be happy with me, but I think everyone should know—Juvena was supposed to get a $2.5 million phase 2 SBIR grant that they last minute didn\'t give us,” Juvena Therapeutics CEO and cofounder Hanadie Yousef, Ph.D., … wiring. They go silent on us,” she said about the expected $2.5 million federal grant.Instead, the Juvena leader received a March 8 email from the National Institutes of Health (NIH) serving as the notice that the decision to fund its phase 2 trial had been denied \"at this time.\" The email, which has been viewed by Fierce Biotech, consisted of one paragraph and did not include the reason for the decision.As of publication, the HHS, NIH and NIA have not responded to Fierce’s … ard process for funding recipients outside of the U.S. A subaward occurs when a grant recipient redirects some of their received funds to a third party, like a research group at another university, which then carries out part of the grant’s work. Before the new structure is fully implemented—which is expected by Sept. 30—the NIH won’t issue any n
Lilly Bites Again in $650M Muscle-Preserving Treatment Pact With Juvena - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Lilly Bites Again in $650M Muscle-Preserving Treatment Pact With Juvena June 11, 2025 | 1 min read | Annalee Armstrong Twitter LinkedIn Facebook Email Print iStock, cienpies The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement wi … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Copy of Case Studies - LifeSci Search Skip to content Home Services and Offerings News & Events Client Success Our Team Contact Us LifeSci Partners Platform Client Success We leverage our unparalleled relationships across the life sciences ecosystem to connect the right leaders with the right companies. Chief Corporate Development Officer C-Suite April 25, 2023 Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced today the hiring of... READ MORE Global life sciences investment
Healthcare Private Placement and M&A Transactions Review Week Ending July 27, 2025 | Silverwood Partners About Us Overview Why Silverwood? Careers Our Location Connect With Us Insights & Analysis Newsletters Intelligence Briefs Events Connect With Us Team All Team Technology Consumer Healthcare Industry Experience Technology Consumer Healthcare Connect With Us Services Mergers & Acquisitions Private Placements Connect With Us Transactions All Transactions Technology Consumer Healthcare Connect With Us Healthcare Private Placement and M&A Transactions Review Week Ending July
Pipeline - Juvena Therapeutics Pipeline Navigation Home Platform Disease Indications Pipeline Team Join Us News Contact Us Home Platform Disease Indications Pipeline Team Join Us News Contact Us Contact 640 Galveston Drive Redwood City, CA 94063 Get Directions » 650.223.5879 [email protected] Stay in touch Subscribe to our newsletter Email Subscribe By entering your email you agree to our Privacy Policy © 2023 Juvena Therapeutics Inc. All Rights Reserved | Privacy Policy Home Platform Disease Indications Pipeline Team Join Us News Contact Us Home Platform Disease Indications Pipeline
Juvena Therapeutics & Eli Lilly and Company ink research collaboration focused on muscle health - Industrial talks --> Toggle navigation HOME ARTICLES INTERVIEWS EVENTS APPOINTMENTS ENEWSLETTERS MAGAZINES BLOG MEDIAKIT ABOUT US CONTACT Search NEWS ABOUT > Biotechnology Clean Rooms Clinical Trials Consultants Digitalization Drug Discovery & Development Engineering Global Pharma Industrial talks Ingredients Lab Equipment Logistics & Distribution Manufacturing Market Outsourcing Packaging Quality / GMP Regulation Safety --> Guía de empresas Guía online Productos Proyectos … and potential development and commercialization milestone payments. Juvena will grant Lilly an exclusive license to identified lead candidates and Lilly will be responsible for further research, development and commercialization. Juvena Therapeutics is achieving this through its fully integrated, end-to-end artificial intelligence (AI)-enabled drug discovery and development platform, JuvNET, that combines a compounding database mapping secreted proteins to specific disease ph
Home - Juvena Therapeutics Unlocking the therapeutic potential of secreted proteins Restoring tissue health and rejuvenating lives Learn about our impact Protein signaling dysregulation leads to degenerative diseases Juvena maps the therapeutic potential of natural secreted proteins and engineers them into biologics that restore tissue homeostasis Restoring tissue health by repairing protein signaling and intercellular communication Secreted proteins are released by cells to direct cellular repair, promote tissue regeneration, and drive healthy communication between different body systems. As
%PDF-1.7 %���� 1 0 obj >/Metadata 832 0 R/ViewerPreferences 833 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x���mo����w��ݴ��=��}�\z\kA����s��������ӗԐ+j���ʾ�?����� G)��o��ϋ�m�����������m�����˯��_�,O?-�V���j�xz����~��rq�ܜ�eo./�� ��������"/�MS���U]��lu^�Y���,���������#�ya��m�"����������nYf��쯱mc�̕4������7�f�w""/tv���Ht>DV˼�:�͎Uvm �e�W_���Nj��Yq�a�x�͖�'���z�� ��x����8.U�BO L~�����fJ`���q��l�*��is5)0� ����d�K�ɜ���}_�ݙ��.
Stephen Juelsgaard, DVM, JD - Juvena Therapeutics Team Back to Careers Stephen Juelsgaard, DVM, JD Stephen Juelsgaard is the former executive vice president, secretary and chief compliance officer of Genentech, Inc. His career at Genentech spanned 24 years. In that role, Dr. Juelsgaard reported to Genentech’s CEO, Art Levinson, and was responsible for Genentech’s Corporate Law, Intellectual Property, Government Affairs (Federal and State), Human Resources, and Healthcare Compliance groups, as well as the Business Services group, which included Strategic Facilities Planning, Corporate Security,
2024 MDF Regional Conference, Los Angeles, CA | Myotonic Dystrophy Foundation Skip to content We’ve refreshed our website! Take a look around, tell us what you think, or revisit the archived site. Save the Date: Join us April 28 - May 2 for the 2027 MDF International Conference in Seattle, Washington! Learn more IMPORTANT: Find all anesthesia guides for individuals and their families and healthcare professionals Anesthesia resources Search ... Results See all results Language Close Language Open Language English Español Deutsch Français Healthcare professionals Close Healthcare professionals O
Hear what Juvena (a.k.a. The Wandering Wasp) has to say on how to overcome fear & self limiting beliefs! Watch our full interview video on our YouTube channel! Link In Bio! #JuvenaHuang #TheWanderingWasp #MotorcycleLife #OverLanding #MotoFocus9tro | 9tro
Pannellum Javascript is required to view this panorama. (It could be worse; you could need a plugin.)
Industry - SCWD Skip to content No results Replay: Annual Conference 2025 About the SCWD Society Scientific Board Get a Membership Annual Conference 18th International Conference 2025 Abstract Submission 2025 Programme 2025 Congress Information 2025 SCWD Virtual 2025 Past events SCWD Publications Digest Guidelines Videos Contact Shopping Cart Your cart is currently empty. Return to shop Username or Email Address Password Remember Me Forgot Password? Log In Username or Email Address Get New Password ← Back to login ➜ Journal of Cachexia, Sarcopenia and Muscle Shopping cart Free 0 Login No resul … eaders, engage in insightful discussions, and expand your professional network. Submit an Abstract 2026 ⟶ Are you ready to share your groundbreaking research and innovative ideas with leading experts in the field? We invite you to submit your abstract for the 2026 conference. Resources Resources Latest ↗ Cachexia ↗ Sarcopenia ↗ Muscle Wasting ↗ Frailty ↗ Ageing ↗ Latest ↗ Cachexia ↗ Sarcopenia ↗ Muscle Wasting ↗ Frailty ↗ Ageing ↗ Nutrition ↗ From the Literature ↗ Cancer Cach
Pulse 2.0 - Juvena Therapeutics: $33.5 Million Series B... Facebook Log In Pulse 2.0's Post Pulse 2.0 January 12 · Shared with Public Juvena Therapeutics: $33.5 Million Series B Raised To Advance Regenerative Biologics Pipeline: Juvena Therapeutics announced it has raised $33.5 million in a Series B financing to advance its clinical-stage regenerative biologics programs and expand its AI-enabled discovery capabilities. The post Juvena Therapeutics: $33.5 Million Series B Raised To Advance Regenerative Biologics Pipeline appeared first on Pulse 2.0. pulse2.com Juvena Therapeutics: $33.5 Mi
We hope to see you at one... - Myotonic Dystrophy Foundation Facebook Log In Myotonic Dystrophy Foundation's Post Myotonic Dystrophy Foundation April 20 · Shared with Public We hope to see you at one of our 2026 Regional Conferences! These one-day, in person conferences offer a robust program built for the DM community! Learn more at: https://myotonic.org/events/conferences/ Thank you to our 2026 Regional Conference sponsors for helping make these events possible: Avidity Biosciences, Dyne Therapeutics , PepGen, ARTHEx biotech , Sarepta, Vertex , 3xGenetics, Juvena Therapeutics, Sanofi, a
CEO Dr. Hanadie Yousef delivered a seminar at the Buck Institute as a distinguished guest speaker highlighting Juvena’s pioneering work in regenerative biologics and AI-driven drug discovery - Juvena Therapeutics News Back to Careers CEO Dr. Hanadie Yousef delivered a seminar at the Buck Institute as a distinguished guest speaker highlighting Juvena’s pioneering work in regenerative biologics and AI-driven drug discovery Navigation Home Platform Disease Indications Pipeline Team Join Us News Contact Us Home Platform Disease Indications Pipeline Team Join Us News Contact Us Contact 640 Galvesto
Our CEO Dr. Hanadie Yousef presented updates on Juvena's platform and advancing pipeline of tissue restorative biologics for muscle and metabolic diseases at Biocom California's Global Life Science Partnering and Investor Conference - Juvena Therapeutics News Back to Careers Our CEO Dr. Hanadie Yousef presented updates on Juvena’s platform and advancing pipeline of tissue restorative biologics for muscle and metabolic diseases at Biocom California’s Global Life Science Partnering and Investor Conference Navigation Home Platform Disease Indications Pipeline Team Join Us Ne
Juvena Therapeutics Funding: How Much Did They Raise & Key Investors Products Product ZoomInfo Copilot AI sales agent GTM Workspace AI workspace for smarter GTM GTM Studio Build and run GTM workflows triggered by buying signals ZoomInfo MCP Connect your AI to verified B2B data Sales Company and contact database Marketing Actionable ABM platform Talent Source the best and brightest Operations Lead routing and data quality Data as a Service ZoomInfo data for your GTM systems Platform Cloud partners Ready, set, integrate Platform overview Connect industry-leading data across your entire tech
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Hanadie Yousef: Cracking the S... - We're not getting any younger... yet. - Apple Podcasts Search Home New Top Charts Search 1 April 35 min Hanadie Yousef: Cracking the Secretome Code We're not getting any younger... yet. Play In this episode, Buck scientist Brianna Stubbs joins Hanadie Yousef, Co-Founder of Juvena Therapeutics, to discuss the cutting-edge of longevity science. Dr. Yousef shares how Juvena is leveraging AI and the secretome—the proteins secreted by stem cells—to develop therapies that target muscle wasting and promote tissue regeneration. From the potential and risks of GLP-1
Juvena Therapeutics - Creative Destruction Lab Applications are open for the 2026/27 Cohort. Apply now! × About Program Streams Locations Staff Putting AI to Work CDL Research Streams Prime (General) Advanced Therapies AgriFood Artificial Intelligence Biomedical Engineering BioTech Cancer Climate Computational Health Compute Defence Digital Society Energy Health Health & Wellness Healthcare Robotics Manufacturing Minerals Neuro Next Gen Computing Oceans Quantum Risk Space Supply Chain Web3 Locations Berlin Calgary Cleveland Doha Estonia Halifax London Melbourne Milan Montreal Paris San Se … xas Toronto Vancouver Wisconsin Mentors Companies Partners Blog Community EN FR Apply About Program Streams Locations Staff Putting AI to Work CDL Research Streams Prime (General) Advanced Therapies AgriFood Artificial Intelligence Biomedical Engineering BioTech Cancer Climate Computational Health Compute Defence Digital Society Energy Health Health & Wellness Healthcare Robotics Manufacturing Minerals Neuro Next Gen Computing Oceans Quantum Risk Space Supply Chain Web3 … xas Toronto Vancouver Wisconsin Mentors Companies Partners Blog Community EN FR Apply Site: CDL-Vancouver Cohort Year: 2020/21 Stream: Health juvenatherapeutics.com Juvena Therapeutics Juvena Therapeutics discovers and develops protein-based therapeutics that promote tissue regeneration to specifically target muscle regeneration, sarcopenia, and other rare degenerative muscle diseases. The Machine Learning (ML)-enhanced discovery platform efficiently identifies lead candidate
What are the primary areas of focus for Juvena Therapeutics? Products Data Feature Plans Request Demo Sign Up for Free What are the primary areas of focus for Juvena Therapeutics? 20 March 2025 Overview of Juvena TherapeuticsCompany ny Background and Mission Juvena Therapeutics is an innovative biopharmaceutical company that emerged from the confluence of decades of academic research and industry experience. Founded in 2017 by Dr. Hanadie Yousef and Dr. Jeremy O’Connell—with backgrounds in aging research, stem cell biology, systems biology, and proteomics—the company is built upon a mission to … t also from collaborative partnerships and prestigious grants. For instance, an award from the California Institute of Regenerative Medicine (CIRM) and applications for additional federal support from the NIH underline the company’s credibility and potential in advancing its lead candidate programs. This confluence of academic rigor, technological innovation, and strategic funding allows Juvena Therapeutics to serve as a paradigm for next-generation biopharmaceutical companie … uvena’s approach and strengthens its strategic foundations. 2. Governmental and Grant-based Collaborations: Beyond private investment, Juvena has secured significant non-dilutive funding through strategic grants. For example, a highly competitive grant from the California Institute of Regenerative Medicine (CIRM) totaling nearly $3.9 million supports the advancement of their lead program, JUV-161, for DM1. These collaborations with governmental agencies are critical sources o … rts iterative improvements in protein engineering workflows. Collaboration with grant-awarding bodies such as CIRM has been crucial in advancing specific therapeutic areas, most notably neuromuscular disorders like DM1. The focus on DM1 is driven by both scientific rationale and the tangible support provided by such grants, which help bridge the gap between preclinical discovery and clinical translation. Additionally, academic partnerships facilitate a feedback loop where cut … ic focus through several strategic initiatives. The company plans to extend the application of its secretome mapping platform beyond the current focus areas to encompass even more indications that are characterized by impaired regenerative capacity. This includes an ambitious drive toward exploring regenerative solutions for cardiometabolic, skel
Press Releases & News Articles - Juvena Therapeutics News Press Releases & News Articles January, 2026 Juvena Therapeutics Raises $33.5M Series B Led by Bison Ventures to Advance Regenerative Biologics Pipeline Read More » October, 2025 AI Excellence: Juvena’s JuvNET Platform Recognized as CEO Dr. Yousef Makes Prestigious Mayfield | Divot AI List Read More » July, 2025 Pharmaphorum Spotlights Juvena’s AI Platform for Muscle and Metabolic Regeneration in Interview with CEO, Dr. Hanadie Yousef Read More » June, 2025 Juvena Therapeutics and Lilly Enter Rese … . Read More » January, 2023 Biocom highlights backgrounds of Catalyst Award winners including CEO Hanadie Yousef Read More » January, 2023 As Juvena continues to welcome a tremendously talented team, we wanted to thank FierceBiotech, Endpoints News, STAT, Longevity.Technology, BioWorld, and BioCentury for highlighting Juvena Therapeutics’ expanded leadership team last week. Juvena is thrilled to have Neil Berkley as Chief corporate development office … o February, 2022 Juvena Therapeutics Awarded Highly Competitive 3.9M CIRM TRAN1 Grant to Advance Lead Program, JUV-161, to Treat Myotonic Dystrophy Type 1 Read More » November, 2021 CIRM Awards Juvena a $3.9M TRAN1 Grant to Advance JUV-161 for Myotonic Dystrophy Type 1 (DM1) Read More » February, 2020 Juvena Therapeutics Interviewed– Embryonic Proteins for Tissue Regeneration- Jan 2020 Read More » January, 2020 Juvena Therapeutics Listed as 1 of
BioCentury - Juvena hires three new senior executives This Edition ARTICLE | Management Tracks Juvena hires three new senior executives Plus: new CEO at ClostraBio, and updates from Cambrian and Pliant By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst January 26, 2023 1:20 AM UTC Three months after raising a $ 41 million series A, human longevity company Juvena Therapeutics Inc. promoted one senior executive and hi r ed three more, to support the expansion of its secreted protein drug discovery platform. The company named Neil Berkley as chief corporate development offic
CEO Dr. Yousef joins the Biotech CEO sisterhood summit to cultivate a community of support for female-led biotech companies and mentorship. Discussions included CEO best practices, wellness, supporting women leaders, and board service. Learn more here where she is quoted. - Juvena Therapeutics News Back to Careers CEO Dr. Yousef joins the Biotech CEO sisterhood summit to cultivate a community of support for female-led biotech companies and mentorship. Discussions included CEO best practices, wellness, supporting women leaders, and board service. Learn more here where she is quoted. Navigation
Trying 2 Learn - Podcast - Apple Podcasts Search Home New Top Charts Search Trying 2 Learn Kyle Valgardson 5.0 (1) Education Updated Biweekly Trying to cut through the advertisements and AI summaries while trying to learn today is difficult. We developed this podcast from 'The Why Science Initiative" to expand learning on any topic to the general public. This is the podcast where the target it to gain a deeper understanding of new research and interesting topics. Sponsored by Quansys Bio and Eagle Works Manufacturing, with Kyle Valgardson as the host. Latest Episode Follow Episodes Apr 7 Vitam … ther guru. It’s about asking: What actually works… and what can I realistically apply in my life? 50 min 11/25/2025 Vitamin/Supplement series episode 1 | Series intro: Starting the Nutraceutical Journey Send us Fan Mail Starting the Nutraceutical Journey: Why We Need to Talk About This Supplements promise health in a bottle—but behind every label is a web of science, sourcing, and sometimes sketchy shortcuts. In this first episode of our Nutraceutical Series, we l
New podcast dropped... - Buck Institute for Research on Aging Facebook Log In Buck Institute for Research on Aging's Post Buck Institute for Research on Aging April 1 · Shared with Public New podcast dropped today!! Buck scientist Brianna Stubbs sits down with Hanadie Yousef, Co-Founder of Juvena Therapeutics, to discuss the cutting-edge of longevity science, moving beyond "snake oil" and into a future where science-based therapies help us stay younger, longer. All reactions: 8 Like Comment
Check out the Pharma Exec Podcast of CEO Dr. Hanadie Yousef's interview for the Emerging Pharma Leader award to learn more about what drives her ambitions for Juvena - Juvena Therapeutics News Back to Careers Check out the Pharma Exec Podcast of CEO Dr. Hanadie Yousef’s interview for the Emerging Pharma Leader award to learn more about what drives her ambitions for Juvena Navigation Home Platform Disease Indications Pipeline Team Join Us News Contact Us Home Platform Disease Indications Pipeline Team Join Us News Contact Us Contact 640 Galveston Drive Redwood City, CA 94063 Get Dire
Juvena's JUV-161 named orphan drug for DM1 by FDA Skip to content For Healthcare Professionals Newsletter Search Search for: Search Toggle navigation Search for: Search For Healthcare Professionals About MD Toggle menu: About MD Muscular dystrophy overview Causes Symptoms Diagnosis Life expectancy Treatments Approved treatments Experimental treatments Non-drug treatments Types Becker muscular dystrophy Bethlem myopathy Congenital muscular dystrophies Duchenne muscular dystrophy Facioscapulohumeral muscular dystrophy Limb-girdle muscular dystrophy Myotonic dystrophy Tibial muscular dystrop … ved as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship. Tags myotonic dystrophy orphan drug status Leave a comment Fill in the required fields to post. Your email address will not be published. Y
Juvena Therapeutics, Author at Juvena Therapeutics Back to Careers Hanadie Yousef, PhD Dr. Hanadie Yousef is a scientist, entrepreneur, seasoned executive, and global thought leader in AI-driven regenerative medicine and longevity. With over two decades of experience in biomedical research, she is the Co-Founder of Juvena Therapeutics, where she served as CEO, CFO, and Board Chair from 2017 to 2025. Since the company’s incorporation, she pioneered its evolution from a platform-driven concept into a venture-backed, clinical-stage biotechnology leader. Under her leadership, Juvena secured over $ … ss Times “Women Who Lead in Life Sciences,” and the Biocom Catalyst Award. Dr. Yousef is a regularly invited speaker at marquee biotech, AI, and healthcare innovation events. She earned her B.S. summa cum laude from Carnegie Mellon University, her PhD from UC Berkeley as an NSF Fellow, and completed a 5-year postdoctoral fellowship at Stanford School of Medicine as an NIH fellow and SPARK scholar. Her lifelong dedication to biomedical research and entr … rd, and his time in industry. Prior to Juvena Therapeutics, in his postdoctoral fellowship at Harvard Medical school in the lab of Steven Gygi, he leveraged large proteomics datasets to build machine learning classifiers to improve protein-protein interaction predictions within the ubiquitin system. He has spearheaded research projects in multiple tier-one research institutions, including Harvard and Stanford, employing a combination of mass spectrometry, high throughput imag … numerous peer-reviewed publications, approved and pending patents, millions in award grant funding as the primary PI, fellowships, and awards. Learn more about Jeremy PubMed Library LinkedIn Back to Careers Priya Handa, PhD Priya Handa, PhD has over 15 years of experience in basic, preclinical and translational research spanning multiple disease areas including metabolic, hepatic, renal and ocular, among others. Prior to joining Juvena Therapeutics, Priya was a Principal Sci … f Science delineating various DNA repair pathways, and received the best thesis award for her dissertation. She did her postdoctoral work at the University of Washington in Seattle on DNA repair and genomic instability. Priya has authored 38 publications including book chapters and reviews, and has presented her findings in numerous international
In Vivo’s 2024 Rising Leaders | Juvena Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy ,
The Cures Within Us (Hanadie Y…–Translating Aging – Apple Podcasts Search Home New Top Charts Search 18 August 2021 39 min The Cures Within Us (Hanadie Yousef — Juvena Therapeutics) Translating Aging Play Dr. Hanadie Yousef is a scientist, aging biology expert and the co-founder and CEO of Juvena Therapeutics, a Palo Alto-based biopharma startup developing protein-based therapeutics to promote tissue regeneration and increase healthspan to prevent, reverse, and cure degenerative diseases. Dr. Yousef joins host Dr. Chris Patil to discuss Juvena’s premise, their use of a machine learning p … l companies in the world Dr. Yousef’s involvement in the On Deck initiative - a fellowship program that seeks to increase the number of scientists, researchers, and inventors in the healthspan and longevity field Advice she would give new entrepreneurs in this field She is fascinated by the study of human centenarians, reproductive aging, and plant aging Her predictions for the field of aging pharma in the next 5-10 years Quotes: “As we all know, tissues deteriorate as we get
Cracking the Secretome Code Click here to sign up for our quarterly newsletter to keep up with the Buck! About The first independent biomedical research institute in the world focused solely on aging Our mission is to end the threat of age-related disease for this and future generations. About us Overview History Leadership Executive Team Board of Trustees Scientific Advisory Board Emeritus Trustees Events Careers Visit Us Science Advancing the frontiers of research on aging Using cutting-edge science to tackle aging, the #1 risk factor for chronic disease. About our research Overview Focus Ar … ike you. Your investment in the Buck Institute for Research on Aging Innovation Fund fuels progress, innovation, and hope, propelling us toward a world where aging is met with vitality, not limitation. Learn how you can support the Buck Areas of Giving Buck Innovation Fund Move the Mountain™ The Center for Healthy Aging in Women Geroscience Education Center for Human Healthspan President’s Circle Impact Circle Planned Giving Ways to Give Donate Now Donate Search #06 April 1, … ues that’s just so rapidly I feel like transforming how we could actually apply that to improving one of the most costly industries out there, right, which is the cost of drug discovery development and just the sheer amount of failures and billions of dollars unfortunately that are spent on really exciting ideas that don’t make it through sort of clinical development or ultimately lead to benefits when being tested in people. We’re starting to get this idea
CEO Dr. Hanadie Yousef discusses Juvena's AI-enabled platform for mapping the therapeutic potential of stem cell secreted proteins and engineering restorative biologics for age-related and chronic diseases on the podcast Impact AI - Juvena Therapeutics News Back to Careers CEO Dr. Hanadie Yousef discusses Juvena’s AI-enabled platform for mapping the therapeutic potential of stem cell secreted proteins and engineering restorative biologics for age-related and chronic diseases on the podcast Impact AI Navigation Home Platform Disease Indications Pipeline Team Join Us News Contact Us H
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Buck Institute podcast on Juvena Therapeutics and stem cell secretome | Eric Verdin posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign
CEO Dr. Hanadie Yousef Interviewed for Translating Aging Podcast, “The Cures Within Us” - Juvena Therapeutics News Back to Careers CEO Dr. Hanadie Yousef Interviewed for Translating Aging Podcast, “The Cures Within Us” Navigation Home Platform Disease Indications Pipeline Team Join Us News Contact Us Home Platform Disease Indications Pipeline Team Join Us News Contact Us Contact 640 Galveston Drive Redwood City, CA 94063 Get Directions » 650.223.5879 [email protected] Stay in touch Subscribe to our newsletter Email Subscribe By entering your email you agree to our Privacy Policy © 20
Hanadie Yousef: Cracking the S… — We're not getting any younger... yet. — Apple Podcasts Buscar Início Novidades Top charts Buscar 1 de abril 35 min Hanadie Yousef: Cracking the Secretome Code We're not getting any younger... yet. Reproduzir In this episode, Buck scientist Brianna Stubbs joins Hanadie Yousef, Co-Founder of Juvena Therapeutics, to discuss the cutting-edge of longevity science. Dr. Yousef shares how Juvena is leveraging AI and the secretome—the proteins secreted by stem cells—to develop therapies that target muscle wasting and promote tissue regeneration. From the potential and
Discovering Protein Drug Candidates with Hanadie Yousef from Juvena Therapeutics Resources Newsletter Articles Podcast Webinars Office Hours Industries Pathology Earth Observation Case Studies Cancer Detection During Surgery Power Plant Emissions Services About About Me Testimonials Portfolio Publications Speaking Media Coverage Book a Call Discovering Protein Drug Candidates with Hanadie Yousef from Juvena Therapeutics November 25, 2024 Episode artwork credit: Stable Diffusion How can advancements in biotechnology and m
Podcasts - Juvena Therapeutics News Podcasts November, 2024 CEO Dr. Hanadie Yousef discusses Juvena’s AI-enabled platform for mapping the therapeutic potential of stem cell secreted proteins and engineering restorative biologics for age-related and chronic diseases on the podcast Impact AI Listen Now » April, 2024 One of In Vivo’s 2024 Rising Leaders, Dr. Hanadie Yousef, CEO of Juvena Therapeutics, talks about the secretome as a source of therapeutics, the company’s lead assets, the future of longevity medicine and learning as you go as a biotech entrepreneur. Liste … cast of CEO Dr. Hanadie Yousef’s interview for the Emerging Pharma Leader award to learn more about what drives her ambitions for Juvena Listen Now » January, 2023 Juvena’s Head of Data Science, Dr. Eddie Moler interviewed about his experiences in data science and AI applied to diagnostics and drug discovery and shares why he is excited about Juvena Listen Now » August, 2021 CEO Dr. Hanadie Yousef Interviewed for Translating Aging Podcast, “The
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Juvena Therapeutics Raises $33.5M Series B Led by Bison Ventures to Advance Regenerative Biologics Pipeline - Jefferson Life Sciences Skip to the content Investing at the frontier of human health Approach About Team Portfolio News Contact Close Menu Approach About Team Portfolio News Contact Portfolio Company News 01/13/2026 Juvena Therapeutics Raises $33.5M Series B Led by Bison Ventures to Advance Regenerative Biologics Pipeline Juvena Therapeutics, a clinical-stage biotechnology company whose AI-enabled regenerative biologics are designed to restore tissue function, today announced its $33.
Clinical & Nonclinical Archives - Juvena Therapeutics Back to Careers Banmeet Anand, PhD Dr. Banmeet Anand’s more than 20 years experience in the discovery and development of antibodies encompasses fusion proteins, naked, ADCs and bi-specific antibodies; small molecules, and cellular therapies (NK-T, CAR-T) at biotechs and large pharma including Harpoon (a subsidiary of Merck & Co. inc.), Astellas and Genentech. As senior vice president of drug development Dr. Anand leads development of Juvena’s biological assets including the pre-clinica
Juvena and Lilly partner on AI for drug discovery | Inside Precision Medicine posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, y
Fenwick Represents Juvena Therapeutics in $33.5M Series B Funding | Fenwick Skip to main content Main navigation Back Services Services Corporate Capital Markets Compensation & Benefits Corporate Governance Corporate Venture ESG & Sustainability Mergers & Acquisitions Private Equity Private Investment Funds Public Companies SPACs Startup & Venture Capital Intellectual Property Copyright Patents & Emerging Technologies Privacy & Cybersecurity Technology Transactions Trademark Litigation Appellate Complex Litigation Consumer Class Actions & Mass Arbitration Copyright … r Offices Service Innovation Community Social Impact Pro Bono Fenwick Community Fund Contact Us Subscribe Careers Careers Students Experienced Attorneys Business Professionals Current Openings Insights Insights Events Crypto Review 2026 CLE Speaker Series What's Trending Search Press Enter to search Clear Search Our Insights Experience Fenwick Represents Juvena Therapeutics in $33.5M Series B Funding Share January 12, 2026 Fenwick Represents Juvena Therapeutics in $33.5M
News Archives - Juvena Therapeutics Back to Careers Juvena Therapeutics Raises $33.5M Series B Led by Bison Ventures to Advance Regenerative Biologics Pipeline Back to Careers Watch CEO Dr. Hanadie Yousef’s lecture at Stanford on AI and Drug Discovery, and Juvena’s unique JuvNET platform Back to Careers CEO Dr. Hanadie Yousef shares more about our JuvNET Platform as an invited seminar speaker for Stanford’s CS 522: Artificial Intelligence in Healthcare course Back to Careers CEO, Dr. Hanadie Yousef, joined the Impact a Billion Summit by Transform VC to share how Juvena is using AI
Juvena Therapeutics and Eli Lilly partner on muscle health | Dr. Hanadie Yousef posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in,
Press Release Distribution and Management Accessibility: Skip TopNav Latest News and Press Releases Want to stay updated on the latest news? Sign into Reader Account Create Reader Account June 11, 2025 07:30 ET | Source: Juvena Therapeutics Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle Health Lilly taps Juvena's AI platform, the first to map the therapeutic potential of secreted proteins, to discover treatments that improve muscle health. May 19, 2025 08:25 ET | Source: Juvena Therapeutics Juvena Therapeutics Announces Initiation of First-in-Human Clinical
Juvena Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 11 May 2026 Juvena Therapeutics, Inc. Startups | Holding Company | 2017 | California, United States | 10-50 | www.juvenatherapeutics.com Startups | Holding Company | 2017 | California, United States | 10-50 | www.juvenatherapeutics.com Last update 11 May 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Nervous System Diseases Other Diseases Skin and Musculoskeletal Diseases Fusio … .businesswire.com Jefferson River Capital Launches New Life Sciences Investment Fund, Jefferson Life Sciences NEW YORK--(BUSINESS WIRE)--Jefferson River Capital today announced the launch of Jefferson Life Sciences, an early-stage life sciences investment firm investing at the frontier of human health. “Now more than ever, the biotech industry needs investors with a long-term view that can help turn bold scientific ideas into meaningful therapeutic solutions for patients in n … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Juvena Therapeutics, Author at Juvena Therapeutics Back to Careers CSO Dr. Jeremy O’Connell and Director Dr. Priya Handa represent Juvena and present our JUV-112 metabolic disease asset at Obesity Week 2024 Back to Careers CEO Dr. Hanadie Yousef discusses Juvena’s AI-enabled proteomics and multimodal platform for decoding therapeutic secreted proteins on the “Leveraging Technology to Advance the Pipeline” panel at Longwood’s Boston CEO summit Back to Careers CEO Dr. Hanadie Yousef was nominated to Founders Forum’s 100 Women Founders to Watch, which shines a
Hanadie served on a CEO panel with a group of portfolio companies for Bascom Ventures (part of Alumni Ventures) - Juvena Therapeutics News Back to Careers Hanadie served on a CEO panel with a group of portfolio companies for Bascom Ventures (part of Alumni Ventures) Navigation Home Platform Disease Indications Pipeline Team Join Us News Contact Us Home Platform Disease Indications Pipeline Team Join Us News Contact Us Contact 640 Galveston Drive Redwood City, CA 94063 Get Directions » 650.223.5879 [email protected] Stay in touch Subscribe to our newsletter Email Subscribe By entering
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle Health - Juvena Therapeutics News Back to Careers Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle Health Navigation Home Platform Disease Indications Pipeline Team Join Us News Contact Us Home Platform Disease Indications Pipeline Team Join Us News Contact Us Contact 640 Galveston Drive Redwood City, CA 94063 Get Directions » 650.223.5879 [email protected] Stay in touch Subscribe to our newsletter Email Subscribe By entering your email you agree to our Privacy Policy © 2023 Juven
Join Us - Juvena Therapeutics Join Us Join Our Team! Our team is growing! We’re seeking individuals that have a passion for computational platforms for drug discovery and development, regenerative medicine, and a desire to be a member of Juvena’s world-class team. At Juvena Therapeutics, we believe everyone deserves a seat at the table and an equal chance at success, regardless of gender, race, sexual orientation, religion, ethnicity, cultural heritage, or age. We Are a Community and a Team Most importantly, we are an equal opportunity employer and respect an individual’s right to freedom of e … our talents to our team? Email a general career inquiry, along with your CV, to [email protected] . Navigation Home Platform Disease Indications Pipeline Team Join Us News Contact Us Home Platform Disease Indications Pipeline Team Join Us News Contact Us Contact 640 Galveston Drive Redwood City, CA 94063 Get Directions » 650.223.5879 [email protected] Stay in touch Subscribe to our newsletter Email Subscribe By entering your email you agree to our Privacy
Board of Directors Archives - Juvena Therapeutics Back to Careers Hanadie Yousef, PhD Dr. Hanadie Yousef is a scientist, entrepreneur, seasoned executive, and global thought leader in AI-driven regenerative medicine and longevity. With over two decades of experience in biomedical research, she is the Co-Founder of Juvena Therapeutics, where she served as CEO, CFO, and Board Chair from 2017 to 2025. Since the company’s incorporation, she pioneered its evolution from a platform-driven concept into a venture-backed, clinical-stage biotechnology leader. Under her leadership, Juvena secured over $1 … ss Times “Women Who Lead in Life Sciences,” and the Biocom Catalyst Award. Dr. Yousef is a regularly invited speaker at marquee biotech, AI, and healthcare innovation events. She earned her B.S. summa cum laude from Carnegie Mellon University, her PhD from UC Berkeley as an NSF Fellow, and completed a 5-year postdoctoral fellowship at Stanford School of Medicine as an NIH fellow and SPARK scholar. Her lifelong dedication to biomedical research and entr … rd, and his time in industry. Prior to Juvena Therapeutics, in his postdoctoral fellowship at Harvard Medical school in the lab of Steven Gygi, he leveraged large proteomics datasets to build machine learning classifiers to improve protein-protein interaction predictions within the ubiquitin system. He has spearheaded research projects in multiple tier-one research institutions, including Harvard and Stanford, employing a combination of mass spectrometry, high throughput imag … numerous peer-reviewed publications, approved and pending patents, millions in award grant funding as the primary PI, fellowships, and awards. Learn more about Jeremy PubMed Library LinkedIn Back to Careers Steven James, MBA Steven James has over 35 years of biopharmaceutical experience and has been involved in building and leading numerous successful companies and the discovery and development of important approved drug products. Mr. James was most recently president, Chief
Horizon Ventures Techcracker conference spotlights Juvena Co-Founder, Hanadie Yousef, PhD as one of 70 founders of innovative new companies developing disruptive technologies that improve lives Oct. 2022 - Juvena Therapeutics News Back to Careers Horizon Ventures Techcracker conference spotlights Juvena Co-Founder, Hanadie Yousef, PhD as one of 70 founders of innovative new companies developing disruptive technologies that improve lives Oct. 2022 Navigation Home Platform Disease Indications Pipeline Team Join Us News Contact Us Home Platform Disease Indications Pipeline Team Join Us News Conta
Join Us - Juvena Therapeutics Join Us Join Our Team! Our team is growing! We’re seeking individuals that have a passion for computational platforms for drug discovery and development, regenerative medicine, and a desire to be a member of Juvena’s world-class team. At Juvena Therapeutics, we believe everyone deserves a seat at the table and an equal chance at success, regardless of gender, race, sexual orientation, religion, ethnicity, cultural heritage, or age. We Are a Community and a Team Most importantly, we are an equal opportunity employer and respect an individual’s right to freedom of e … our talents to our team? Email a general career inquiry, along with your CV, to [email protected] . Navigation Home Platform Disease Indications Pipeline Team Join Us News Contact Us Home Platform Disease Indications Pipeline Team Join Us News Contact Us Contact 640 Galveston Drive Redwood City, CA 94063 Get Directions » 650.223.5879 [email protected] Stay in touch Subscribe to our newsletter Email Subscribe By entering your email you agree to our Privacy
Juvena Therapeutics | | The Pharmaletter Saturday 27 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematology Cardio Vascular Diabetes Cell And Gene Ther … and potential development and commercialization milestone payments. Juvena will grant Lilly an exclusive license to identified lead candidates, with Lilly responsible for further research, development, and commercialization. Juvena's lead asset, JUV-161, is a muscle-regenerating biologic currently in Phase 1 clinical trials for the treatment of Myotonic Dystrophy Type 1 and sarcopenia. The company is also advancing JUV-112, a preclinical candidate targeting obesity and m
Steven James, MBA - Juvena Therapeutics Team Back to Careers Steven James, MBA Steven James has over 35 years of biopharmaceutical experience and has been involved in building and leading numerous successful companies and the discovery and development of important approved drug products. Mr. James was most recently president, Chief Executive Officer and director of Pionyr Immunotherapeutics until it was acquired by Ikena Oncology. Previously, he was president, Chief Executive Officer and director of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Mr. James was
Lilly taps Juvena's AI to tackle muscle health in $650M pact | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Juvena Therapeutics CEO Hanadie Yousef Steps Down Amid Clinical Trials | Longevity.Technology posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to jo … s Acquisition of Lisata, L-Nutra’s $36 Million Series D, BIOMAKERS’s $8 Million Fund Raise , a daily summary of financings for therapeutic biotechnology company executives and investors - www.collabrityreport.com Think Bioscience EXCIVA GmbH enGene Erasca, Inc. Lisata Therapeutics, Inc. GSK BIOMAKERS 1 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Chris Lehman 5mo Edited Report this post January 20 - 21, 2026 headlines: Think Bioscience’s $55 M … s Acquisition of Lisata, L-Nutra’s $36 Million Series D, BIOMAKERS’s $8 Million Fund Raise , a daily summary of financings for therapeutic biotechnology company executives and investors - www.collabrityreport.com Think Bioscience EXCIVA GmbH enGene Erasca, Inc. Lisata Therapeutics, Inc. GSK BIOMAKERS 8 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Decentralised Digital Asset Fund 88 followers 5mo Report this post **Investment Announcement** We’
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Invest In Juvena Therapeutics Stock | Buy Pre-IPO Shares | EquityZen We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences Sign Up Today and Learn More About Juvena Therapeutics Stock Invest in or calculate the value of your shares in Juvena Therapeutics or other pre-IPO companies through EquityZen's platform. Get Started View More Companies Juvena Therapeutics Stock (JUTH) Juvena Therapeutics is a biopharmaceutical platform which is discovering novel protein-based therapeutics. Invest Now Sell Shares About Juvena Therapeutics Stock F … their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investmen … on FINRA’s BrokerCheck . EquityZen Inc. was awarded a 2024 Fintech Breakthrough Award by Tech Breakthrough LLC on March 19, 2025, based on the prior year and covering calendar year 2024, and has compensated FinTech Breakthrough LLC for use of its name and logo in connection with the award. FinTech Breakthrough LLC is a third party and has no affiliation with EquityZen. EquityZen created the ticker symbols referenced on this page for use solely on the EquityZen platform. They
Home - Juvena Therapeutics --> Mapping Secreted Proteins to Unmet Medical Needs Our mission is to unlock the therapeutic potential of secreted proteins and to engineer them into life-saving therapeutics About Juvena Juvena Therapeutics is a venture-backed biotechnology company unlocking the therapeutic potential of stem cell-secreted proteins and accelerating their development into life-saving therapeutics for chronic and age-related diseases. We are achieving this through an Artificial Intelligence-enabled platform that combines a compounding database mapping secreted proteins to specif
Developing treatments for muscular dystrophies and metabolic diseases - Juvena Therapeutics Pioneering therapeutics for myopathies and metabolic diseases Muscular dystrophies Metabolic diseases Restoring muscular and metabolic function through innovative biologics Myopathies and metabolic diseases can result from a breakdown within the complex intercellular protein signaling pathways in the body. Until now, the available tools for mapping this biology limited the development of regenerative therapies and a significant unmet need exists. Juvena targets the dysregulation of proteins by engineeri
Juvena Therapeutics’ Partnership with Eli Lilly Featured in Nature Biotechnology for Enhancing Muscle Health and Body Composition - Juvena Therapeutics News Back to Careers Juvena Therapeutics’ Partnership with Eli Lilly Featured in Nature Biotechnology for Enhancing Muscle Health and Body Composition Navigation Home Platform Disease Indications Pipeline Team Join Us News Contact Us Home Platform Disease Indications Pipeline Team Join Us News Contact Us Contact 640 Galveston Drive Redwood City, CA 94063 Get Directions » 650.223.5879 [email protected] Stay in touch Subscribe to our ne
Dr Priya Handa presents Juvena's JUV-161 data at ICFSR Conference | Juvena Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join … verly, MA)! Our senior principal research scientist, ZHEN CHEN , will speak on "Application of DNA Encoded Libraries to Solute Carrier Drug Discovery." Solute carriers are a challenging and underexplored target class. In this talk, we’ll share how DNA-encoded libraries can help identify novel ligands and advance discovery efforts against these important proteins. #SLC #drugdiscovery #keystone 27 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Sre
Juvena is a proud sponsor and honored to be participating in the Myotonic Dystrophy Foundation Annual conference that begins today through tomorrow! The conference brings together the community of… | Juvena Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choice
ENDO 2026 Skip to main content Toggle navigation Search Home Facebook Post Print Neuroendocrinology and Pituitary SUN-040 - JUV-161 as A Disease-Modifying Therapeutic for Myotonic Dystrophy Type 1 Sunday, June 14, 2026 9:00 AM - 4:00 PM CT Location: ENDOExpo; Poster Floor Co-Author(s) AK Ashil Korrane, n/a Juvena Therapeutics Redwood city, California, United States HK Hee Ju Kim, n/a Juvena Therapeutics Redwood city, California, United States Submitting author(s) RD Ritwik Datta, PhD Scientist-II Juvena therapeutics San Francisco, United States Abstract Poster Presenter(s) RD Ritwik Datta, PhD
Juvena announces that... - Myotonic Dystrophy Foundation Facebook Log In Myotonic Dystrophy Foundation's Post Myotonic Dystrophy Foundation January 24, 2024 · Shared with Public Juvena announces that JUV-161, a biologic treatment of DM1, has received positive FDA feedback & Orphan Disease Designation (ODD). Human trials of this treatment are anticipated to commence this year. Read the full announcement at: https://www.businesswire.com/.../Juvena-Therapeutics... All reactions: 43 5 comments 11 shares Like Comment Most relevant Top fan Ronnie Curnutt I'd do it 2y Cecilia Stearns Wi
Development of a Novel Fusion Protein, JUV-161, that Enhances Muscle Regeneration for Treatment of Myotonic Dystrophy Type 1 - MDA Clinical & Scientific Conference 2026 and tags on every page of your site. --> Register Now --> Home MDA Conference 2026 Registration Rates Agenda Location & Venue Our Sponsors CE Media Information Sponsorships & Exhibits Sponsorship Levels Event Sponsorships Marketing Sponsorships Exhibit Information Patient Advocacy Pavilion Abstracts 2026 Abstract Guidelines 2026 Abstract Library 2025 Abstract Library 2024 Abstract Library 2023 Abstract Library 202 … Demand Conference About Us About The MDA Conference About MDA Awards MDA Legacy Award for Achievement in Clinical Research The MDA Donavon Decker Community Impact in Research Award MDA Research Momentum Award Future Conferences Contact Us Home MDA Conference 2026 Registration Rates Agenda Location & Venue Our Sponsors CE Media Information Sponsorships & Exhibits Sponsorship Levels Event Sponsorships Marketing Sponsorships Exhibit Information Patient Advocacy Pavilio … Demand Conference About Us About The MDA Conference About MDA Awards MDA Legacy Award for Achievement in Clinical Research The MDA Donavon Decker Community Impact in Research Award MDA Research Momentum Award Future Conferences Contact Us Development of a Novel Fusion Protein, JUV-161, that Enhances Muscle Regeneration for Treatment of Myotonic Dystrophy Type 1 Topic: Pre-Clinical Research Poster Number: T315 Author(s): Hee Ju Kim, Juvena Therapeutics, Ashil Koranne, Juvena T
Videos - Juvena Therapeutics News Videos November, 2025 Watch CEO Dr. Hanadie Yousef’s lecture at Stanford on AI and Drug Discovery, and Juvena’s unique JuvNET platform Watch Now » September, 2025 CEO Dr. Hanadie Yousef featured on Biotech TV’s Biotech CEO Sisterhood series at the NYSE, spotlighting Juvena’s leadership in protein-based therapeutics for muscle and metabolic disease Watch Now » July, 2025 ‘Insulin for muscle’ and the AI platform behind it, with CEO Dr. Hanadie Yousef Watch Now » June, 2025 Who Are Today’s Biotech Underdogs and What Will
Careers Archives - Juvena Therapeutics Back to Careers Vice President, Chemistry, Manufacturing, and Controls (CMC) Position Description Juvena Therapeutics is seeking a seasoned and strategic leader to join our executive team as the Vice President of Chemistry, Manufacturing, and Controls (CMC). Reporting directly to the SVP of Drug Development, this pivotal role will be responsible for defining and executing the comprehensive CMC strategy for our portfolio from discovery through to clinical-stage development. The successful candidate will lead all aspects of process development, analytical d … tions, and let’s grow together at https://www.juvenatherapeutics.com/careers/ . Apply For The Position Please email your CV and Cover Letter to [email protected] with the title of the position as the subject line. Notice: JavaScript is required for this content. Navigation Home Platform Disease Indications Pipeline Team Join Us News Contact Us Home Platform Disease Indications Pipeline Team Join Us News Contact Us Contact 640 Galveston Drive Redwood City, CA 94063
%PDF-1.6 %���� 1 0 obj >/OCGs[17 0 R 19 0 R 20 0 R 21 0 R 22 0 R 23 0 R 24 0 R 25 0 R 26 0 R 27 0 R 28 0 R 29 0 R 30 0 R 31 0 R 32 0 R 33 0 R 18 0 R 34 0 R 35 0 R 36 0 R 37 0 R 38 0 R]>>/Pages 3 0 R/Type/Catalog>> endobj 2 0 obj >stream application/pdf MDF_2023_Poster_V3 2023-08-29T15:13:47-07:00 2023-08-29T15:13:47-07:00 2023-08-29T15:13:47-07:00 Adobe Illustrator 27.8 (Macintosh) 256 132 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8f … q�=�㎽�{6�� � D�\�s[Q�q~�� �z��pn � =v-^=�!���5��h���ݵ�R> � v�*I:t9���MiX��rFP�6}g�F���EԱ�y�1�ڇ�#�C���g ��os#��~�x��^�����n�z��o�sC� |� ��Z�Q��Npy;��-��J ��z�Eu�a�Ѩ�4A�d�1��4Ѥ�X��P�������1��NS��#N�:���e��Ȣ�� , � {㜽p�"(�K���Vm��}�]p�3��������=����3�;�gnMљ}i�M 2w�>��7g63t r����U�/l�������; �!��0��=��L|S���Qf��1J-21fDipVd��!�ޢn�{�� F�� � Fr�Ƒ� 5x� }�� �n�R'ҝ1�sX]�FC�b�烥tu��+�r��-�띒�ZK��Qe��3�ga K�0����08[L��u�e�u�>��7�͖�`(M�~eC��Ԙ�W���� … >����C5�Dʒ��ě7��\0 �umP�r�t���M���������$�G|�Gy�q UZGK[Zt�:e�hAѩE �9�RFp,LK+� ���RH{'�n�Kv7{��;�w��=߽7�(�! �NK���,d�0�̔���$�L����~����[�3'�Ma|R��U��1�/~�ϯ���#8�F�� $��w c>\SZ��ܻ���~G�/��Q,$��hXP�w7����:�}�ئ�%KS� [6�ؒEo:n1�\M Eb����z�!iLֽ/�qW����v.����_�.8 �� �5n��E0��p�9J����Qw1`_!f�ߤ ��̑�;C �b�zA�G��u �%O���}$� �����;6 r,������)4ۿ��=��h)6-��֕��R�ʡ� s*s ���>~�o�f�C���du�-z �~c �y�C^=`��`�{K�B떍�9�t'���!{ro�\ '���r�"��/��ڷT��@@�= � … �)S��D�p= B����E8ciQ����"�s�RZ���.�Ύ2�0Pf9H �����S�����V)�(�f����rFP)e�zdym=�u)jkc��gj${�.}b=;y# ��/�� ��[@�g�=��H�^�&O��=��X�7��W+r�! ��)�_��|�I��Gt��� ~f9��������;�G�{�|佧{g ��_7��b��K�Q��H:+ ���rTY � �C� �#�y����*`�봟j������w�'�mH7Gp�a[�pm|t �����{;#�ټ$n�/���2mn"9�8���|��H��2��/�|�$�,{�pB��[�%K��۲�� �,>$Y���5�ϥ˒�C>p��6,^b�K�{�����ꧧ������S���+�� r�kԷz� h�Z�un�|�IWA�|4���1Ε�_Z��_��Z �^Z��@��js��B� |�� Ϟȟ�¾ �Ԃ�L0��V5�
Join Us - Juvena Therapeutics Join Us Join Our Team! Our team is growing! We’re seeking individuals that have a passion for computational platforms for drug discovery and development, regenerative medicine, and a desire to be a member of Juvena’s world-class team. At Juvena Therapeutics, we believe everyone deserves a seat at the table and an equal chance at success, regardless of gender, race, sexual orientation, religion, ethnicity, cultural heritage, or age. We Are a Community and a Team Most importantly, we are an equal opportunity employer and respect an individual’s right to freedom of e … our talents to our team? Email a general career inquiry, along with your CV, to [email protected] . Navigation Home Platform Disease Indications Pipeline Team Join Us News Contact Us Home Platform Disease Indications Pipeline Team Join Us News Contact Us Contact 640 Galveston Drive Redwood City, CA 94063 Get Directions » 650.223.5879 [email protected] Stay in touch Subscribe to our newsletter Email Subscribe By entering your email you agree to our Privacy
Jobs at Juvena Therapeutics | Felicis You are using an outdated browser. Please upgrade your browser to improve your experience and security. About Team Portfolio Focus Areas AI Cybersecurity & Defense Global Resilience & Energy Health and Bio Fellows Blog About Team Portfolio Focus Areas AI Cybersecurity & Defense Global Resilience & Energy Health and Bio Fellows Blog Powered by Consider Privacy Terms company Portfolio Jobs subscribe Subscribe socials Request an AI SuMMARY Fortune Favors The Brave terms and conditions privacy policy © 2026 Felicis ALL RIGHT RESERVED
Juvena Therapeutics and Lilly Enter Research Collaboration --> Accessibility: Skip TopNav Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle Health June 11, 2025 07:30 ET | Source: Juvena Therapeutics Juvena Therapeutics Research will leverage world’s first AI-enabled screening platform for mapping the therapeutic potential of secreted signaling proteins, developed by Juvena Collaboration aims to accelerate the discovery of treatments that help individuals maintain and even improve their muscle mass and function REDWOOD CITY, Calif., June 11, 2025 (GLOBE NEWSWI … and potential development and commercialization milestone payments. Juvena will grant Lilly an exclusive license to identified lead candidates and Lilly will be responsible for further research, development and commercialization. About Juvena Therapeutics Juvena Therapeutics is a platform-driven, clinical-stage company unlocking the therapeutic potential of stem-cell secreted proteins and translating them into a growing pipeline of engineered biologics for chronic muscle and
Juvena Therapeutics - Jefferson Life Sciences Skip to the content Investing at the frontier of human health Approach About Team Portfolio News Contact Close Menu Approach About Team Portfolio News Contact ← Back to All Companies Juvena Therapeutics About Juvena Therapeutics is a computationally-driven biopharmaceutical company on a mission to research, develop, and commercialize tissue restorative biologics to treat myopathies and metabolic diseases. We are achieving this through a fully integrated, end-to-end artificial intelligence-enabled platform that combines a diverse protein librar
Juvena Therapeutics | Intellectual Property & Industry Research Alliances Skip to main content | Office of the Vice Chancellor for Research Toggle navigation Intellectual Property & Industry Research Alliances Search Terms Submit Search About About Our Office Our Impact Our Team Diversity and Equity Socially Responsible Licensing Startups Launched All Advanced Materials Agriculture BSAC-Affiliated Startup Communications, Information Technology, and Data Processing Electronic Systems and Components Energy Environment Medical Devices Medical Diagnostics Medical Therapeutics Research Tool